Pharmaceutical shares hit by anti-rebate law

Published: 2010-05-04 06:59:00

Updated: 2010-05-04 06:59:00

Influenced by the recent passage of an anti-rebate bill and poor performance of local leading drugmakers in the first quarter, pharmaceutical shares posted losses on April 29.

"This shows the current pharmaceutical shares’ rally depends heavily on outer impacts and business performance," said ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK